CATALOGO DEI PRODOTTI DELLA RICERCA

BONIFACIO, Massimiliano
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 9.589
EU - Europa 8.864
AS - Asia 7.291
SA - Sud America 1.100
AF - Africa 203
OC - Oceania 52
Continente sconosciuto - Info sul continente non disponibili 8
AN - Antartide 1
Totale 27.108
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.397
RU - Federazione Russa 3.560
SG - Singapore 2.730
CN - Cina 2.232
GB - Regno Unito 1.575
IT - Italia 964
BR - Brasile 872
HK - Hong Kong 704
VN - Vietnam 664
DE - Germania 546
SE - Svezia 491
FR - Francia 470
IE - Irlanda 416
FI - Finlandia 308
KR - Corea 242
IN - India 158
UA - Ucraina 117
CA - Canada 100
NL - Olanda 94
AR - Argentina 86
ID - Indonesia 74
PL - Polonia 69
JP - Giappone 65
BD - Bangladesh 64
MX - Messico 61
TR - Turchia 59
AU - Australia 46
ES - Italia 45
BE - Belgio 42
IQ - Iraq 42
NG - Nigeria 40
AT - Austria 36
ZA - Sudafrica 33
EC - Ecuador 31
CO - Colombia 29
PK - Pakistan 28
VE - Venezuela 27
UZ - Uzbekistan 25
CL - Cile 24
IR - Iran 24
MA - Marocco 23
TG - Togo 22
PH - Filippine 19
TN - Tunisia 18
RO - Romania 16
AZ - Azerbaigian 15
MY - Malesia 15
JO - Giordania 14
NP - Nepal 14
SA - Arabia Saudita 14
CZ - Repubblica Ceca 13
DZ - Algeria 13
GR - Grecia 13
BJ - Benin 12
AE - Emirati Arabi Uniti 11
LT - Lituania 11
PE - Perù 11
CH - Svizzera 10
DK - Danimarca 10
KZ - Kazakistan 10
PY - Paraguay 9
EG - Egitto 8
IL - Israele 8
BO - Bolivia 7
CG - Congo 7
KE - Kenya 7
NO - Norvegia 7
RS - Serbia 7
SI - Slovenia 7
AL - Albania 6
CR - Costa Rica 6
JM - Giamaica 6
KG - Kirghizistan 6
LV - Lettonia 6
OM - Oman 6
TH - Thailandia 6
BH - Bahrain 5
ET - Etiopia 5
NZ - Nuova Zelanda 5
PT - Portogallo 5
SY - Repubblica araba siriana 5
TW - Taiwan 5
EU - Europa 4
HU - Ungheria 4
LK - Sri Lanka 4
PA - Panama 4
QA - Qatar 4
UY - Uruguay 4
AM - Armenia 3
BY - Bielorussia 3
DO - Repubblica Dominicana 3
GE - Georgia 3
HR - Croazia 3
KH - Cambogia 3
LA - Repubblica Popolare Democratica del Laos 3
LY - Libia 3
NI - Nicaragua 3
SN - Senegal 3
A2 - ???statistics.table.value.countryCode.A2??? 2
BG - Bulgaria 2
Totale 27.071
Salva come PNG Salva come JPEG
Città #
Singapore 1.384
Southend 1.303
Ashburn 1.187
Moscow 1.160
Chandler 968
Dallas 941
San Jose 941
Hong Kong 694
Woodbridge 505
Beijing 504
Dublin 414
Verona 407
The Dalles 403
Ann Arbor 329
Jacksonville 268
Houston 265
New York 198
Ho Chi Minh City 194
Wilmington 194
Lawrence 172
Princeton 172
Los Angeles 171
Hanoi 141
Jinan 133
Nanjing 123
Shenyang 123
Munich 97
Buffalo 92
Helsinki 89
Redmond 88
São Paulo 82
Council Bluffs 81
Redondo Beach 78
Sindelfingen 78
Columbus 77
Hebei 76
Santa Clara 71
Tianjin 69
Tokyo 59
Warsaw 58
Zhengzhou 54
Milan 53
Orem 53
Changsha 48
London 47
Falls Church 46
Nanchang 46
Jakarta 45
Taizhou 45
Fuzhou 44
Ningbo 44
Bologna 43
Guangzhou 43
Redwood City 43
Chicago 42
Montreal 42
Brussels 41
Dong Ket 40
Hangzhou 39
Nuremberg 39
Chennai 38
Frankfurt am Main 38
Haikou 37
Turku 37
Seoul 36
Seattle 35
San Francisco 33
Rome 32
Atlanta 31
Rio de Janeiro 31
Abuja 30
Norwalk 30
Amsterdam 27
Belo Horizonte 27
Denver 27
Jiaxing 27
Kent 27
Taiyuan 25
Boardman 24
Johannesburg 24
Mexico City 24
Stockholm 24
Tashkent 24
Perth 23
Phoenix 23
Poplar 23
Boston 22
Falkenstein 22
Lomé 22
Groningen 21
Da Nang 18
Toronto 18
Shanghai 17
Vienna 17
Dearborn 16
Provo 16
Biên Hòa 15
Brasília 15
Düsseldorf 15
Haiphong 15
Totale 16.292
Salva come PNG Salva come JPEG
Nome #
Epidemiology of mastocytosis in adults based on a multidisciplinary diagnostic approach. 330
CD66b-CD64dimCD115- cells in the human bone marrow represent neutrophil-committed progenitors 250
Notch singalling inhibition as a multi-target therapy to overcome bone marrow microenvironment-mediated drug resistance in AML 247
Role of GSK-3 signalling in non-promyelocitic acute myeloid leukemia (AML) cell response to chemotherapy 247
Notch signalling drives bone marrow stromal cell-mediated chemoresistance in acute myeloid leukemia 246
A study of the crosstalk between CD30 and CXCR4 243
BCR-ABL fusion transcript b2a2 is associated with a higher risk of non-optimal early response in CP-CML patients treated with standard dose imatinib: a study from Gruppo Triveneto LMC. 243
CAL2 Monoclonal Antibody Is a Rapid and Sensitive Assay for the Detection of Calreticulin Mutations in Essential Thrombocythemia and May Provide Prognostic Informations 243
Role of Wnt/β-Catenin Signalling in Acute Myeloid Leukemia (AML) Cell Response to Chemotherapy 239
A preliminary experience with the HyperCHiDAM Verona intensive chemotherapy regimen in heavily pretreated refractory Hodgkin's lymphoma 235
Inhibition of GSK-3 Signalling Enhances Sensitivity of Non-Promyelocitic Acute Myeloid Leukemia (AML) Cell to Chemotherapy 231
Bone mineral density, bone turnover markers and fractures in patients with indolent systemic mastocytosis 224
Clonal mast cell disorders limited to bone marrow: not a negligible disease. 224
Absence of TCL1A expression is a useful diagnostic feature in splenic marginal zone lymphoma. 223
Rational of targeting WNT/beta-catenin signaling in acute myeloid leukemia (AML) 215
Anaphylactic Reactions After Discontinuation of Hymenoptera Venom Immunotherapy: A Clonal Mast Cell Disorder Should Be Suspected 215
Inhibition of Notch signalling overcomes bone marrow stromal-mediated anti-apoptotic and chemoresistance effects in AML. 211
CXCL12 and [N33A]CXCL12 in 5637 and HeLa Cells: Regulating HER1 Phosphorylation via Calmodulin/Calcineurin 211
Autoimmune complications are frequent in splenic and nodal marginal zone lymphomas 209
ALK-positive anaplastic large cell lymphoma with PAX-5 expression: report of a case 208
Longitudinal Evaluation of Bone Mineral Density and Bone Metabolism Markers in Patients with Indolent Systemic Mastocytosis Without Osteoporosis 205
CAL2 monoclonal antibody is a rapid and sensitive assay for the detection of calreticulin mutations in essential thrombocythemia and may provide prognostic informations 205
A simple score predicts clonal mast cell disorders in patients with systemic reactions to Hymenoptera venom without skin lesions 203
Clonal mast cell disorders in patients with severe Hymenoptera venom allergy and normal serum tryptase levels 202
Predictive factors of stable deep molecular response in chronic myeloid leukemia patients treated with imatinib standard dose: a study from the Gruppo Triveneto LMC. 200
Value of flow cytometry in the diagnosis of indolent systemic mastocytosis. 198
Assessment of the interlaboratory variability and robustness of JAK2V617F mutation assays: A study involving a consortium of 19 Italian laboratories 197
Predictors of stable deep molecular response in chronic phase chronic myeloid leukemia patients treated with dasatinib or nilotinib after imatinib failure 196
Predictors for response to ruxolitinib in real-life: an observational independent study on 266 patients with myelofibrosis 194
A Survey on Clinical and Biological Characteristic and Therapy Management of an Italian Series of 455 Adult Patients with Systemic Mastocytosis on Behalf of Italian Registry of Mastocytosis 189
Somatic D816V KIT mutation in a case of adult-onset familial mastocytosis. 188
α-bisabolol is an effective proapoptotic agent against BCR-ABL+ cells in synergism with Imatinib and Nilotinib 187
Inhibition of Notch signaling enhances chemosensitivity in B cell precursor acute lymphoblastic leukemia 184
Back to life – Living, treating, managing myelofibrosis: the burden of illness for patients and their families 183
Regulative Loop between β-catenin and Protein Tyrosine Receptor Type γ in Chronic Myeloid Leukemia 183
A Multidisciplinary Diagnostic Approach Reveals a Higher Prevalence of Indolent Systemic Mastocytosis: 15-Years’ Experience of the GISM Network 183
CAL2 monoclonal antibody is a rapid and sensitive assay for the detection of calreticulin mutations in essential thrombocythemia patients 182
The Sesquiterpene Oil {alpha}-Bisabolol Induces Apoptosis of B-Chronic Lymphocytic Leukemia Primary Cells 181
Combination of EUTOS score and 3-month BCR-ABL transcript level identifies a group of good-risk chronic myeloid leukemia patients with favorable response to frontline imatinib therapy 181
Improved detection of the C-KIT D816V mutation using allele-specific arms real time PCR assay allows a finer recognition of patients with indolent systemic mastocytosis. 180
The impact of sensitive KIT D816V detection on recognition of Indolent Systemic Mastocytosis 180
BLAST: A Confirmatory, Single-Arm, Phase 2 Study of Blinatumomab, a Bispecific T-Cell Engager (BiTE®) Antibody Construct, in Patients with Minimal Residual Disease B-Precursor Acute Lymphoblastic Leukemia (ALL) 178
Small Molecule Inhibitors of Microenvironmental Wnt/β-Catenin Signaling Enhance the Chemosensitivity of Acute Myeloid Leukemia 178
Plasmacytoid dendritic cell leukemia: a rapidly evolving disease presenting with skin lesions sensitive to radiotherapy plus hyperthermia. 176
Predictors for Response to Ruxolitinib in Real-Life: An Observational Independent Study on 408 Patients with Myelofibrosis 174
Notch Signaling Molecules as Prognostic Biomarkers for Acute Myeloid Leukemia 174
Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation 174
Imatinib-treated chronic myeloid leukemia patients with discordant response between cytogenetic and molecular tests at 3 and 6 month time-points have a reduced probability of subsequent optimal response 173
The serological prevalence of SARS-CoV-2 infection in patients with chronic myeloid leukemia is similar to that in the general population 172
Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis 171
Therapeutic targeting of Lyn kinase to treat chorea-acanthocytosis 171
Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients 170
Characterization of a new B-ALL cell line with constitutional defect of the Notch signaling pathway 169
Comparison of dasatinib and nilotinib as second-line therapy after imatinib failure in chronic phase chronic myeloid leukemia patients. 166
Multiple large osteolytic lesions in a patient with systemic mastocytosis: a challenging diagnosis 165
Pro-apoptotic activity of α-bisabolol in preclinical models of primary human acute leukemia cells 164
Molecular “warning” CML patients: a retrospective study of Gruppo Triveneto LMC. 164
Dickkopf-1 and sclerostin serum levels in patients with systemic mastocytosis 164
Bone Disease in Mastocytosis 164
Isolated bone marrow mastocytosis: an underestimated subvariant of indolent systemic mastocytosis 162
Short-term, intensive chemotherapy regimen is equally effective in Burkitt lymphoma (BL) and in the novel WHO 2008 entity “B-cell lymphoma intermediate between DLBCL and BL". 162
Uncovering two neutrophil-committed progenitors that immediately precede promyelocytes during human neutropoiesis 161
A successful treatment-free remission is achievable also by chronic myeloid leukemia patients lacking optimal requirements 160
Real-life comparison of dasatinib and nilotinib as second-line therapy after imatinib failure for chronic phase CML 159
Efficacy of tyrosine kinase inhibitors in Ph-like acute lymphoblastic leukemia harboring ABL-class rearrangements 159
Ultra-deep sequencing (UDS) allows more sensitive detection of the D816V and other KIT gene mutations in systemic mastocytosis 158
Unexpected subacute leucoencephalopathy following intrathecal methotrexate and cytarabine administration in a patient homozygous for MTHFR 677C→T polymorphism. 157
Systemic mastocytosis: a muldisciplinary approach (Review) [Lamastocitosi sistemica: Un approccio multidiscliplinare] 156
A critical comparison of Sokal, Euro, and Eutos risk scores in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors. 156
Mitochondrial-Mediated Apoptosis by the Sesquiterpene Oil {alpha}-Bisabolol and Its Synergism with Imatinib and Nilotinib In BCR-ABL+ Cells. 155
Efficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: Results from an independent study 155
TP53 mutations in adult acute lymphoblastic leukemia (ALL) are relatively frequent in molecularly negative case of both B- and T-lineage and correlate with poor response to induction therapy 154
The impact of a 7-day prednisone (PDN) pretreatment in adult (less than 60y) acute lymphoblastic leukemia (ALL) therapy: results of LAL2000 vs LAL0496. 153
Clinical presentation and management practice of systemic mastocytosis. A survey on 460 Italian patients 153
Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study⁎ 153
Regulative loop between beta-catenin and protein tyrosine phosphatase receptor type gamma (PTPRG) in chronic myeloid leukemia 152
Excellent outcomes of 2G-TKI therapy after imatinib failure in chronic phase CML patients 152
Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart 151
Serum tryptase levels differently change over time in indolent systemic mastocytosis with or without skin lesions. 151
Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms 150
Sesquiterpene α-bisabolol, which binds to Bid in lipid rafts, induces apoptosis in BCR/ABL+ cell lines through membrane depolarization. 149
EUTOS Score Identifies Cases with Poor Outcome in Patients with Early Chronic Phase Chronic Myeloid Leukemia, Though Not Predictive for Optimal Response to Imatinib 149
Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients 149
Modified HyperCVAD and rituximab for the treatment of B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma. 148
Arterial thrombosis in Philadelphia-negative myeloproliferative neoplasms predicts second cancer: a case-control study 148
High incidence of autoimmune complications in 82 patients with non-MALT marginal zone lymphomas. 144
Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient-based survey on 1133 patients 144
Hyperchidam Verona897 Regimen Is Effective in Treatment of Advanced Peripheral T Cell Lymphoma (PTCL): The GITIL Experience in 33 Cases 143
Hymenoptera Anaphylaxis and C-kit Mutations: An Unexpected Association 143
Systemic mastocytosis associated with myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis: Report of three cases 139
Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study 139
BCR-ABL mutations in chronic myeloid leukemia (CML) patients (pts) with failure and warning to first- and second-lline tyrosine kinase inhibitor (TKI) therapy: what is the advantage of Next-Generation Sequencing (NGS) over conventional sequencing? 138
Intensive short-term chemotherapy regimen induces high remission rate (over 90%) and event-free survival both in children and adult patients with advanced sporadic Burkitt lymphoma/leukemia 137
Bosutinib in the real-life treatment of chronic myeloid leukemia patients aged $greater$65~years resistant/intolerant to previous tyrosine-kinase inhibitors 137
PBX/E2A transcript positive B-lymphoblastic leukemia (B-ALL) presenting with bilateral renal and myocardial involvement: a case report. 135
Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors in the real-life practice: Identification of risk factors and the role of prophylaxis 135
EUTOS Score Predicts Optimal Response To Imatinib According To The Revised ELN Recommendations Better Than Sokal Score: A Study From The “Gruppo Triveneto LMC” 131
Clinical features and survival of patients with indolent systemic mastocytosis defined by the updated WHO classification 131
Ultra-Deep Sequencing (UDS) Allows More Sensitive Detection of the D816V and Other Kit Gene Mutations in Systemic Mastocytosis 130
High levels of tumor load reduction after intensive chemotherapy favorably affect the prognosis of BCR/ABL+ ALL adult patients receiving Imatinib Mesylate alone as a post-consolidation treatment according to the Italian GIMEMA LAL 0201/A protocol 130
Totale 17.830
Salva come PNG Salva come JPEG
Categoria #
all - tutte 91.214
article - articoli 61.437
book - libri 0
conference - conferenze 29.329
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 448
Totale 182.428
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021276 0 0 0 0 0 0 0 0 0 20 162 94
2021/20221.381 106 374 36 141 109 56 24 73 72 40 78 272
2022/20232.692 190 264 263 470 208 704 33 152 297 24 46 41
2023/20241.596 73 128 90 158 175 197 63 109 27 86 379 111
2024/20254.293 188 241 214 703 183 141 210 238 629 318 425 803
2025/202612.229 881 747 903 2.060 3.080 800 1.182 748 1.053 775 0 0
Totale 27.428